单药吉西他滨治疗老年晚期非小细胞肺癌疗效观察

目的观察单药吉西他滨治疗老年晚期非小细胞肺癌的疗效和不良反应。方法收集Ⅲ～Ⅳ期老年非小细胞肺癌患者54例，根据是否应用吉西他滨分为试验组和对照组，试验组30例患者应用单药吉西他滨800～1 000 mg/m2，第1、8天静脉滴注，21天为1周期，至少2周期；对照组给予最佳支持治疗。结果30例患者均可评价疗效，其中，完全缓解0例，部分缓解9例，有效率为30.0%(9/30)。中位疾病进展时间（TTP）为4.9月，中位生存期为6.5月。主要不良反应多为Ⅰ～Ⅱ度骨髓抑制及皮疹。结论单药吉西他滨治疗老年晚期非小细胞肺癌是安全有效的。

Clinical Observation of Gemcitabine Monotherapy in Treatment of Elder Advanced Non-small Cell Lung Cancer

ObjectiveTo observe the clinical efficacy and toxicity of Gemcitabine monotherapy in the treatment of elder advanced non-small cell lung cancer(NSCLC). MethodsFifty four eldly patients with stage Ⅲ~Ⅳ non-small cell lung cancer were randomly divided into test group and control group depending on using or not using Gemcitabine for treatment. Thirty cases of test group were treated with Gemcitabine 800～1000 mg/m2 on d1,8 intravenously. Repeated every 21 days and with at least 2 cycles. Control group was given the best supportive care. ResultsIn the 30 evaluable cases, CR was observed in 0 case and PR in 9 cases, the total response rate was 30.0%(9/30). Median time to progression (TTP) of all the patients was 4.9 months, and median survival time was 6.5 months. The main side effect was decrease of leucopenia and platelet, but most of them were at gradeⅠ~Ⅱ. ConclusionGemcitabine monotherapy is effective and safe in the treatment of elder advanced NSCLC. The toxicities were well tolerated.